Chil Covid-19 Antigen Rapid Test 40Test/Box
CHIL COVID-19 Antigen Rapid Test Device was compared to RT-PCR in an evaluation performed on 372 samples in the period May to October 2021. 102 positive and 270 negative samples were confirmed by RT-PCR by using nasopharyngeal swab. Over-all sensitivity was found as 95.39 % and the specificity was 99.04 %, compared to the RT-PCR results. CHIL Covid-19 Antigen Rapid Test had a higher detection limit corresponding approximately to 30 TCID50/mL. There was 20 false negative patient and it was over 30 Ct (cylcle threshold) values which is low positive when we categorized the Ct values as high positive (Ct 20-25), moderate positive (Ct 25-30) and low positive(Ct >30).
Interference testing was performed to evaluate CHILD COVID-19 Antigen Rapid Test performance with common substances. The study is designed as to test the below substances in the absence or presence of approximately 1125 TCID50/mL (3x LoD) SARS-CoV-2 virus obtained from NIBSC company (SARS-CoV-2 fully infectious virus (strain BetaCoV/Australia/VIC01/2020; grown in VeroE6/TMPRSS2 cell line passage 4; 9.73x106 TCID50/mL.). All the experiments were carried out in triplicate.
No interference effect was observed for the common substances on the CHILD COVID-19.
The study is intended to test the CHIL COVID-19 Antigen Rapid Test for the high concentration of SARS-CoV-2 for the Hook effect.
CHIL COVID-19 Antigen Rapid Test Device was compared to RT-PCR in an evaluation performed on 372 samples in the period May to October 2021. 102 positive and 270 negative samples were confirmed by RT-PCR by using nasopharyngeal swab. Over-all sensitivity was found as 95.39 % and the specificity was 99.04 %, compared to the RT-PCR results. CHIL Covid-19 Antigen Rapid Test had a higher detection limit corresponding approximately to 30 TCID50/mL. There was 20 false negative patient and it was over 30 Ct (cylcle threshold) values which is low positive when we categorized the Ct values as high positive (Ct 20-25), moderate positive (Ct 25-30) and low positive(Ct >30).
Interference testing was performed to evaluate CHILD COVID-19 Antigen Rapid Test performance with common substances. The study is designed as to test the below substances in the absence or presence of approximately 1125 TCID50/mL (3x LoD) SARS-CoV-2 virus obtained from NIBSC company (SARS-CoV-2 fully infectious virus (strain BetaCoV/Australia/VIC01/2020; grown in VeroE6/TMPRSS2 cell line passage 4; 9.73x106 TCID50/mL.). All the experiments were carried out in triplicate.
No interference effect was observed for the common substances on the CHILD COVID-19.
The study is intended to test the CHIL COVID-19 Antigen Rapid Test for the high concentration of SARS-CoV-2 for the Hook effect.
CHIL COVID-19 Antigen Rapid Test Device was compared to RT-PCR in an evaluation performed on 372 samples in the period May to October 2021. 102 positive and 270 negative samples were confirmed by RT-PCR by using nasopharyngeal swab. Over-all sensitivity was found as 95.39 % and the specificity was 99.04 %, compared to the RT-PCR results. CHIL Covid-19 Antigen Rapid Test had a higher detection limit corresponding approximately to 30 TCID50/mL. There was 20 false negative patient and it was over 30 Ct (cylcle threshold) values which is low positive when we categorized the Ct values as high positive (Ct 20-25), moderate positive (Ct 25-30) and low positive(Ct >30).
Interference testing was performed to evaluate CHILD COVID-19 Antigen Rapid Test performance with common substances. The study is designed as to test the below substances in the absence or presence of approximately 1125 TCID50/mL (3x LoD) SARS-CoV-2 virus obtained from NIBSC company (SARS-CoV-2 fully infectious virus (strain BetaCoV/Australia/VIC01/2020; grown in VeroE6/TMPRSS2 cell line passage 4; 9.73x106 TCID50/mL.). All the experiments were carried out in triplicate.
No interference effect was observed for the common substances on the CHILD COVID-19.
The study is intended to test the CHIL COVID-19 Antigen Rapid Test for the high concentration of SARS-CoV-2 for the Hook effect.